Biomedical Sciences - Cancer Research | Cancer Proteomics
Cancer Proteomics
From Bench to Bedside
Daoud, Sayed S. (Ed.)
2008, XII, 264 p. 5 illus. in color., Hardcover
ISBN: 978-1-58829-858-4
This item usually ships in 2-3 business days.
- Comprehensive look at the use of proteomic strategies in cancer therapy
- Covers all the latest technologies used in proteomics
- Includes in-depth information on the human proteome and the role of the FDA in regulating the use of proteomics
- The latest research on proteomics and tyrosine kinases, p53 signalling and tumor biomarkers
- Discusses the future uses of proteomics in therapeutic individualization and target discovery
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
Written for » Research
Keywords » Bioinformatics - Cancer Research - Oncology - Proteomics
Related subjects » Biochemistry & Biophysics - Cancer Research - Oncology & Hematology
Table of contentstableOfContents
PART 1 PROTEOMICS TECHNOLOGIES
- Current and emerging mass spectrometry instrumentation and methods for proteomic analyses. Belinda Willard, Suma Kaveti and Michael T. Kinter
PART 2 CELL SIGNALING PROTEOMICS
2 Integration of genomics and proteomics in dissecting p53 signaling. Kyunghee Lee, Tao Wang, Abdur Rehman, Yuhua Wang, Sayed S. Daoud
3 Proteomic profiling of tyrosine kinases as pharmacological endpoints for
targeted cancer therapy. Moulay A. Alaoui-Jamali and Devanand Pinto
PART 3 TUMOR PROTEOMICS
- Oncoproteomics for personalized management of cancer. K. K. Jain
- Application of serum and tissue proteomics to understand and detect solid tumors. Christina M. Annunziata, Dana M. Roque, Nilofer Azad, Elise C. Kohn
- Insight on renal cell carcinoma proteome. Cecilia Sarto, Vanessa Proserpio, Fulvio Magni, Paolo Mocarelli
- Proteomics in lung cancer. M.A. Reymond, M. Beshay, H. Lippert
- Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. Bjørn Tore Gjertsen, Gry Sjøholt
- New tumor biomarkers: Practical considerations prior to clinical application. Nils Brünner, Mads Holten-Andersen, Fred Sweep, John Foekens, Manfred Schmitt, Michael J Duffy
- Annotating the human proteome: From establishing a parts list to a tool
- Regulatory aspects of the oncology drug-diagnostics co-development
PART 4 BIOINFORMACTICS AND REGULATORY ASPECTS OF PROTEOMICS
for target identification. Rolf Apweiler and Michael Mueller
process by proteomics approach. Dave Li, Joseph Hackett, Maria Chan, Gene Pennello, Steve Gutman
Services for this book
-
Order Online Book Review Copy
Order Online Book Review Copy
Close
New Book Alert
Get alerted on new Springer publications in the subject area of Cancer Research.
